Scouring through corporate communications and broker research isn’t enough Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The ...
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results